BLCM
$1.84
Bellicum Pharma Comm
BLCM
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Thursday
Feb 3
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when BLCM reports earnings?
Beat
Meet
Miss

Where is BLCM's stock price going from here?
Up
Flat
Down
Stock chart of BLCM
Analysts
Summary of analysts' recommendations for BLCM
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas.
Peers
Vertex PharmaceuticalsUltragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalMerck & Co.ZoetisEli LillyBristol-Myers SquibbPfizerInterCept